» Articles » PMID: 9573104

Generation of Neutralizing Antipeptide Antibodies to the Enzymatic Domain of Pseudomonas Aeruginosa Exotoxin A

Overview
Journal Infect Immun
Date 1998 May 9
PMID 9573104
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Burn patients suffer a break in the physical barrier (skin), which, when combined with their generalized state of immunodeficiency, creates an open window for opportunistic infections, mainly with Pseudomonas aeruginosa. Infection of the burn wound has always been a major factor in retardation of wound healing, and sepsis remains the leading cause of death in burn patients. Because studies have shown that topical treatment with antiexotoxin A (ETA) antibodies significantly increases survival in rats infected with toxin-producing strains of P. aeruginosa, we examined 11 synthetic peptides encompassing 12 to 45 amino acid (aa) residues, representing what were predicted by computer analysis to be the most hydrophilic and antigenic regions of ETA. These synthetic peptides were injected into rabbits for antibody production. Different groups of rabbits were immunized with a combination of peptides, with each combination representing one of the three distinct domains of ETA. Animals immunized with various peptide combinations produced peptide-specific antibodies that exhibited cross-reactivity to ETA. Two major epitopes were identified on the ETA molecule by experiments with peptide-specific antibodies in enzyme-linked immunosorbent assay and immunoprecipitation. One of these epitopes was located in the translocation domain (II) (aa 297 to 310), while the other was mapped to the last 13 aa residues at the carboxy-terminal end of the enzymatic domain (III) (aa 626 to 638). Of these two regions, the epitope in the enzymatic domain induced a much higher level of neutralizing antibodies that abrogated the cytotoxic activity of ETA in vitro. Antibodies to this epitope blocked the ADP-ribosyltransferase activity of ETA and appeared to interfere with binding of the substrate elongation factor 2 to the enzymatic active site of the ETA molecule. We conclude that polyclonal, as well as monoclonal, antibodies to short peptides, representing small regions of ETA, may have therapeutic potential in passive immunization or topical treatment of burn patients infected with toxin-producing strains of P. aeruginosa.

Citing Articles

Preparation and evaluation of the exotoxin A nano-gold conjugate as a vaccine candidate for infections.

Abbasi M, Tanomand A, Kafilzadeh F, Zolghadri S, Hosainzadegan H Iran J Basic Med Sci. 2022; 24(10):1366-1372.

PMID: 35096294 PMC: 8769522. DOI: 10.22038/IJBMS.2021.58367.12960.


Isolation and characterizations of a novel recombinant scFv antibody against exotoxin A of Pseudomonas aeruginosa.

Shadman Z, Farajnia S, Pazhang M, Tohidkia M, Rahbarnia L, Najavand S BMC Infect Dis. 2021; 21(1):300.

PMID: 33761869 PMC: 7992942. DOI: 10.1186/s12879-021-05969-0.


Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model.

Manafi A, Kohanteb J, Mehrabani D, Japoni A, Amini M, Naghmachi M BMC Microbiol. 2009; 9:23.

PMID: 19183501 PMC: 2644702. DOI: 10.1186/1471-2180-9-23.


Helicobacter pylori specific immune response induced by conservative flagellin linear B-cell epitope.

Ji W, Hu J, Wu K, Qiu J, Han Z, Ding J World J Gastroenterol. 2005; 11(23):3528-32.

PMID: 15962368 PMC: 4315954. DOI: 10.3748/wjg.v11.i23.3528.


Elucidation of eukaryotic elongation factor-2 contact sites within the catalytic domain of Pseudomonas aeruginosa exotoxin A.

Yates S, Merrill A Biochem J. 2004; 379(Pt 3):563-72.

PMID: 14733615 PMC: 1224111. DOI: 10.1042/BJ20031731.


References
1.
Heggers J, Haydon S, Ko F, Hayward P, CARP S, ROBSON M . Pseudomonas aeruginosa exotoxin A: its role in retardation of wound healing: the 1992 Lindberg Award. J Burn Care Rehabil. 1992; 13(5):512-8. View

2.
LIU P, Yoshii S, Hsieh H . Exotoxins of Pseudomonas aeruginosa. II. Concentration, purification, and characterization of exotoxin A. J Infect Dis. 1973; 128(4):514-9. DOI: 10.1093/infdis/128.4.514. View

3.
Van Dullemen H, van Deventer S, Hommes D, Bijl H, Jansen J, Tytgat G . Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995; 109(1):129-35. DOI: 10.1016/0016-5085(95)90277-5. View

4.
Staugas R, Harvey D, Ferrante A, Nandoskar M, Allison A . Induction of tumor necrosis factor (TNF) and interleukin-1 (IL-1) by Pseudomonas aeruginosa and exotoxin A-induced suppression of lymphoproliferation and TNF, lymphotoxin, gamma interferon, and IL-1 production in human leukocytes. Infect Immun. 1992; 60(8):3162-8. PMC: 257297. DOI: 10.1128/iai.60.8.3162-3168.1992. View

5.
Farahbakhsh Z, Wisnieski B . The acid-triggered entry pathway of Pseudomonas exotoxin A. Biochemistry. 1989; 28(2):580-5. DOI: 10.1021/bi00428a025. View